Short Report: Prevalence of Cognitive Impairment in Newly Diagnosed Relapsing-Remitting Multiple Sclerosis

DiGiuseppe, Giulia; Blair, Mervin; Morrow, Sarah A.

doi:10.7224/1537-2073.2017-029

Cited by 35 publications

(29 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Almost thirty years ago, in a population-based study performed by S. Rao et al, a 45% frequency of cognitive impairment in MS was found [12]. Other epidemiological studies reported frequencies of cognitive impairment in patients with MS between 40–70% in North America and Europe [19]. Frequencies of 40–60% have been reported in Latin America [20].…”

Section: Cognitive Impairment In Multiple Sclerosismentioning

confidence: 99%

Assessment and Impact of Cognitive Impairment in Multiple Sclerosis: An Overview

Islas

Ciampi

2019

Biomedicines

View full text Add to dashboard Cite

Cognitive impairment affects 40–60% of patients with multiple sclerosis. It may be present early in the course of the disease and has an impact on a patient’s employability, social interactions, and quality of life. In the last three decades, an increasing interest in diagnosis and management of cognitive impairment has arisen. Neuropsychological assessment and neuroimaging studies focusing on cognitive impairment are now being incorporated as primary outcomes in clinical trials. However, there are still key uncertainties concerning the underlying mechanisms of damage, neural basis, sensitivity and validity of neuropsychological tests, and efficacy of pharmacological and non-pharmacological interventions. The present article aimed to present an overview of the assessment, neural correlates, and impact of cognitive impairment in multiple sclerosis.

show abstract

Section: Cognitive Impairment In Multiple Sclerosismentioning

confidence: 99%

Assessment and Impact of Cognitive Impairment in Multiple Sclerosis: An Overview

Islas

Ciampi

2019

Biomedicines

View full text Add to dashboard Cite

show abstract

“…MS is an immune-mediated disease that causes CNS damage in the form of demyelination and neurodegeneration. In addition to physical disability, learning and memory impairments occur in approximately half of all patients with MS. 1,2 The exact cause of MS is unknown, but dysregulated glutamate signaling and aberrant T-cell activation are consistently implicated as contributors to both physical and cognitive disease pathogenesis. 3–6 A number of trials have been conducted to identify either a disease-modifying therapy or a novel pharmacotherapy to treat MS-related cognitive impairment.…”

mentioning

confidence: 99%

Glutamine antagonism attenuates physical and cognitive deficits in a model of MS

Hollinger

Smith

Kirby

et al. 2019

Neurol Neuroimmunol Neuroinflamm

View full text Add to dashboard Cite

ObjectiveTo measure the impact of JHU-083, a novel prodrug of the glutamine antagonist 6-diazo-5-oxo-l-norleucine, on immune cell proliferation and activation, along with physical and cognitive impairments associated with the experimental autoimmune encephalomyelitis (EAE) mouse model of MS.MethodsSplenic-derived T cells and bone marrow–derived dendritic cells (DCs) were cultured, activated, and treated daily with vehicle or JHU-083. Proliferation and activation were measured via flow cytometry and IncuCyte live cell analysis. C57BL/6 mice were immunized for EAE. Vehicle or JHU-083 was administered orally every other day either from the time of immunization in the prevention paradigm or from the time of disease onset in the treatment paradigm. Disease scores and body weight were monitored. In the treatment paradigm, cognition was evaluated using the Barnes maze test.ResultsJHU-083 selectively inhibits T-cell proliferation and decreases T-cell activation, with no effect on DCs. In vivo, orally administered JHU-083 significantly decreases EAE severity in both prevention and treatment paradigms and reverses EAE-induced cognitive impairment.ConclusionsJHU-083, a well-tolerated, brain penetrable glutamine antagonist, is a promising novel treatment for both the physical and cognitive deficits of MS.

show abstract

“…Approximately 40-65% of people living with multiple sclerosis (MS) have difficulties with cognition [1][2][3]. With an average onset age of 30 years [4] and an unpredictable course (e.g.…”

Section: Introductionmentioning

confidence: 99%

Evaluating the feasibility and preliminary efficacy of a Cognitive Occupation-Based programme for people with Multiple Sclerosis (COB-MS): protocol for a feasibility cluster-randomised controlled trial

Dwyer

Alvarez‐Iglesias

Joyce

et al. 2020

Trials

View full text Add to dashboard Cite

Background: Cognitive difficulties experienced by people with multiple sclerosis (MS) impact their quality of life and daily functioning, from childcare and work, to social and self-care activities. Despite the high prevalence of cognitive difficulties seen in MS, there is a lack of developed programmes that target cognition, while also supporting patients by helping them to function well in everyday life. The Cognitive Occupation-Based programme for people with MS (COB-MS) was developed as a holistic, individualised cognitive rehabilitation intervention. It addresses the wide-ranging symptoms and functional difficulties that present in MS, including the ability to maintain employment, social activities, home management and self-care. The aim of the current research is to evaluate the feasibility and preliminary efficacy of COB-MS for people with MS. The focus is on feasibility outcomes as well as functioning associated with cognitive difficulty and secondary outcomes related to cognition, fatigue and quality of life. Methods: One hundred and twenty people with MS will be assigned to participate in either the COB-MS programme or a treatment as usual, wait-list control group as part of this single-blind, cluster-randomised controlled feasibility and preliminary efficacy trial of the COB-MS programme. The COB-MS group will participate in an eight-session occupational-based cognitive rehabilitation programme over 9 weeks. The primary outcome measure is the goal attainment scaling at 12 weeks. Participants will be assessed pre-intervention, post-intervention and at 12 weeks post-intervention and 6 months post-intervention. Qualitative evaluations of participants' perspectives will also be examined as part of the feasibility study. Discussion: Results will provide recommendations for a future definitive trial of COB-MS, with respect to both feasibility and preliminary, clinical efficacy. In the event that results indicate efficacy, study findings will suggest that COB-MS requires consideration as a means of enhancing cognitive and daily functioning in people living with MS.

show abstract

Short Report: Prevalence of Cognitive Impairment in Newly Diagnosed Relapsing-Remitting Multiple Sclerosis

Cited by 35 publications

References 26 publications

Assessment and Impact of Cognitive Impairment in Multiple Sclerosis: An Overview

Assessment and Impact of Cognitive Impairment in Multiple Sclerosis: An Overview

Glutamine antagonism attenuates physical and cognitive deficits in a model of MS

Evaluating the feasibility and preliminary efficacy of a Cognitive Occupation-Based programme for people with Multiple Sclerosis (COB-MS): protocol for a feasibility cluster-randomised controlled trial

Contact Info

Product

Resources

About